Bryan M. Lewis

756 total citations
7 papers, 475 citations indexed

About

Bryan M. Lewis is a scholar working on Oncology, Molecular Biology and Cell Biology. According to data from OpenAlex, Bryan M. Lewis has authored 7 papers receiving a total of 475 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 3 papers in Molecular Biology and 2 papers in Cell Biology. Recurrent topics in Bryan M. Lewis's work include Cancer Treatment and Pharmacology (5 papers), Cancer therapeutics and mechanisms (2 papers) and Microtubule and mitosis dynamics (2 papers). Bryan M. Lewis is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), Cancer therapeutics and mechanisms (2 papers) and Microtubule and mitosis dynamics (2 papers). Bryan M. Lewis collaborates with scholars based in United States and Japan. Bryan M. Lewis's co-authors include Xiaojie Zhu, Bruce A. Littlefield, Mary Ann Jordan, Leslie Wilson, Olga Azarenko, Jennifer Smith, Masataka Hikota, Dale L. Boger, Wanjun Zheng and Melvin J. Yu and has published in prestigious journals such as Biochemistry, Cancer Research and The Journal of Organic Chemistry.

In The Last Decade

Bryan M. Lewis

7 papers receiving 462 citations

Peers

Bryan M. Lewis

ONCOL

MB

OC

CB

PHARM

Bruce F. Wels United States

Cheryl Napier United States

S E Holwell United Kingdom

Peter Sicinski United States

Wenjian Min China

Pamela Rutherford United States

David Paladino United States

Mutsumi Okamura Japan

Hisashi Yoshimi Japan

Shin‐ichi Yaguchi Japan

Bruce F. Wels United States

Bryan M. Lewis

114 ×0.4

ONCOL

133 ×0.9

MB

127 ×1.2

OC

49 ×0.5

CB

88 ×1.2

PHARM

Citations per year, relative to Bryan M. Lewis Bryan M. Lewis (= 1×) peers Bruce F. Wels

Countries citing papers authored by Bryan M. Lewis

Since Specialization

Citations

This map shows the geographic impact of Bryan M. Lewis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bryan M. Lewis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bryan M. Lewis more than expected).

Fields of papers citing papers by Bryan M. Lewis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bryan M. Lewis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bryan M. Lewis. The network helps show where Bryan M. Lewis may publish in the future.

Co-authorship network of co-authors of Bryan M. Lewis

This figure shows the co-authorship network connecting the top 25 collaborators of Bryan M. Lewis. A scholar is included among the top collaborators of Bryan M. Lewis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bryan M. Lewis. Bryan M. Lewis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Lewis, Bryan M., Charles W. Chase, Francis G. Fang, et al.. (2013). Process Development of Halaven®: Synthesis of the C1-C13 Fragment from d-(-)-Gulono-1,4-lactone. Synlett. 24(3). 323–326. 25 indexed citations

2.

Narayan, Sridhar, Hongsheng Cheng, Hong Du, et al.. (2011). Novel second generation analogs of eribulin. Part II: Orally available and active against resistant tumors in vivo. Bioorganic & Medicinal Chemistry Letters. 21(6). 1634–1638. 12 indexed citations

3.

Narayan, Sridhar, Hongsheng Cheng, Hong Du, et al.. (2011). Novel second generation analogs of eribulin. Part I: Compounds containing a lipophilic C32 side chain overcome P-glycoprotein susceptibility. Bioorganic & Medicinal Chemistry Letters. 21(6). 1630–1633. 16 indexed citations

4.

Narayan, Sridhar, Hongsheng Cheng, Hong Du, et al.. (2011). Novel second generation analogs of eribulin. Part III: Blood–brain barrier permeability and in vivo activity in a brain tumor model. Bioorganic & Medicinal Chemistry Letters. 21(6). 1639–1643. 16 indexed citations

5.

Towle, Murray J., Kathleen A. Salvato, Bruce F. Wels, et al.. (2010). Eribulin Induces Irreversible Mitotic Blockade: Implications of Cell-Based Pharmacodynamics for In vivo Efficacy under Intermittent Dosing Conditions. Cancer Research. 71(2). 496–505. 111 indexed citations

6.

Smith, Jennifer, Leslie Wilson, Olga Azarenko, et al.. (2009). Eribulin Binds at Microtubule Ends to a Single Site on Tubulin To Suppress Dynamic Instability. Biochemistry. 49(6). 1331–1337. 245 indexed citations

7.

Boger, Dale L., Masataka Hikota, & Bryan M. Lewis. (1997). Determination of the Relative and Absolute Stereochemistry of Fostriecin (CI-920). The Journal of Organic Chemistry. 62(6). 1748–1753. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact